TSW
PLXP

Thompson Siegel & Walmsley’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Thompson Siegel & Walmsley’s Portfolio PLXP Stock Details PLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-600
Closed -$70K – 919
2016
Q3 		$70K Buy
+600
New +$58.5K ﹤0.01% 460

Other funds holding PLXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MC
Middleton & Co Boston, Massachusetts $877M AUM 15.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Thompson Siegel & Walmsley's PLXP Position: Q4 2016 in Review

Thompson Siegel & Walmsley sold out of PLx Pharma Inc. Common Stock (PLXP) in Q4 2016, closing a stake of 600 shares — an estimated $70K sold.

Thompson Siegel & Walmsley first reported a position in PLXP in Q3 2016 and held it in 1 quarter. The position peaked at $70K in Q3 2016. 19 funds tracked by Wall St. Rank hold PLXP as of Q4 2016.

  • Thompson Siegel & Walmsley reported no remaining PLx Pharma Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 600 PLx Pharma Inc. Common Stock shares in Q4 2016, an estimated $70K.
  • Thompson Siegel & Walmsley first reported a position in PLx Pharma Inc. Common Stock in Q3 2016 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's PLx Pharma Inc. Common Stock position peaked at $70K in Q3 2016.
  • 19 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q4 2016.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2016, filed 13 Feb 2017.